Business
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES, May 08, 2025--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.
About this update from Puma Biotechnology Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":800,"url":"https://media.zenfs.com/en/business-wire.com/5c62a9a8572aae57edfef47505107c2c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/u13KOvc9PXBGPy3JY3_9Zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5c62a9a8572aae57edfef47505107c2c","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/si70psvlUXEh5F_Dhotk7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5c62a9a8572aae57edfef47505107c2c","width":1200,"height":400}},"lazy":false},{"type":"text","content":"LOS ANGELES, May 08, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024.","length":299,"tagName":"p"},{"type":"text","content":"Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024.","length":255,"tagName":"p"},{"type":"text","content":"Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 2025, compared to net loss of $4.8 million, or $0.10 per basic and diluted share, for the first quarter of 2024.","length":296,"tagName":"p"},{"type":"text","content":"Non-GAAP adjusted net income was $5.0 million, or $0.10 per basic and diluted share, for the first quarter of 2025, compared to non-GAAP adjusted net loss of $2.4 million, or $0.05 per basic share and diluted share, for the first quarter of 2024. Non-GAAP adjusted net income (loss) excludes stock-based compensation expense. For a reconciliation of GAAP net income (loss) to non-GAAP adjusted net income (loss) and GAAP net income (loss) per share to non-GAAP adjusted net income (loss) per share, please see the financial tables at the end of this news release.","length":563,"tagName":"p"},{"type":"text",...